Clinical Trial: Phase II Study of LW402 in Moderate-to-Severe Atopic Dermatitis

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186387) titled 'Phase II Study of LW402 in Moderate-to-Severe Atopic Dermatitis' on Sept. 15.

Brief Summary: This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.

Study Start Date: May 11, 2023

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis (AD)

Intervention: DRUG: LW402

LW402 tablets

DRUG: LW402 placebo

LW402 placebo tablets

Recruitment Status: COMPLETED

Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....